Next Steps Using Anti-CD19 Therapies in DLBCL
The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
R/R DLBCL: Educating Patients About CAR T Cells
Suggestions to hematologist-oncologists when talking to patients with relapsed/refractory diffuse large B-cell lymphoma about the potential benefits of CAR T-cell therapy and toxicities.
CAR T Cells in R/R DLBCL
Recommendations to increase the uptake of CAR T-cell therapies into clinical practice when managing patients with relapsed/refractory diffuse large B-cell lymphoma.
Anti-CD19 Therapy for DLBCL: Treatment Selection
Variables that are likely to impact the use of loncastuximab vs a combination approach with tafasitamab and lenalidomide to treat relapsed/refractory diffuse large B-cell lymphoma.
Loncastuximab for R/R DLBCL
An overview of the LOTIS-1 clinical trial and the rationale for the accelerated approval of loncastuximab for relapsed/refractory diffuse large B-cell lymphoma.
Anti-CD19 Targeted Therapy for DLBCL: Safety and Efficacy
Recommendations for managing patients with diffuse large B-cell lymphoma on tafasitamab.
Novel Frontline Approaches Under Study for R/R DLBCL
An overview of potential strategies being explored to improve frontline therapy with R-CHOP for patients with relapsed/refractory diffuse large B-cell lymphoma.
Frontline Therapy for R/R DLBCL: TAFA/LEN/R-CHOP
Drs John M. Burke and Marin F. Xavier consider the potential utilization of tafasitamab plus lenalidomide plus R-CHOP chemotherapy vs R-CHOP chemotherapy alone as relapsed/refractory diffuse large B-cell lymphoma treatment.
Individualized Therapy for Unfit Patients With R/R DLBCL
Implications for treating unfit patients with relapsed/refractory diffuse large B-cell lymphoma with chemotherapy or the combination of tafasitamab and lenalidomide based on patient characteristics and the L-MIND trial.
R/R DLBCL: Treating Fit Patients Who Are Transplant Eligible
Recommendations for approaching patients with relapsed/refractory diffuse large B-cell lymphoma with newer targeted treatment approaches as frontline therapy vs referral for transplant.
CD19-Targeted Therapy for DLBCL
The rationale for sequencing therapy with CD19-targeted agents when managing patients with various subtypes of diffuse large B-cell lymphoma.
DLBCL: Prognosis and Goals of Therapy
Variables that impact a patient with diffuse large B-cell lymphoma, and prognosis and strategies for counseling patients on goals of therapy.
DLBCL: Approaches for Monitoring Frontline Treatment Response
Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.
DLBCL Risk Status and Frontline Treatment Decisions
The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.
DLBCL: Frontline Therapy for GCB and ABC Subtypes
A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.
Classifying and Stratifying Patients With DLBCL
A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.